Insulet Corp. logo
PODDInsulet Corp.

Current vs Average Debt/Equity Ratio

Debt/Equity Ratio

How the latest reported debt/equity ratio of 0.73 compares to its TTM/3Y/5Y/10Y/15Y/20Y averages as of Tuesday, March 31, 2026.

PODD Debt/Equity Ratio

PODD Current vs Average Debt/Equity Ratio

PODD Debt/Equity Ratio vs Average

CURRENT VS TTM AVG

-17.47%

CURRENT VS 3Y AVG

-51.78%

CURRENT VS 5Y AVG

-63.51%

CURRENT VS 10Y AVG

-71.97%

CURRENT VS 15Y AVG

-69.45%

CURRENT VS 20Y AVG

-65.44%

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy